


Patient flow diagram and analysis cohorts

Treatment-naïve ascitic fluid cohort for flow cytometry, clinical outcomes, CRS, and targeted sequencing



Supplementary Fig. S1. Patient flow diagram and analysis cohorts. Flow diagram showing the distribution of the treatment-naïve ascitic fluid cohort across flow cytometric, clinical outcome, chemotherapy response, survival, and molecular analysis subsets. A total of 133 ascitic fluid samples were included, comprising high-grade serous ovarian carcinoma (HGSOC, n = 69), non-ovarian carcinoma (NOC, n = 31), and non-malignant ascites (NM, n = 33). Different denominators across subsequent analyses reflect differences in the availability of complete follow-up, chemotherapy response score assessment, and targeted sequencing data. *BRCA*^{WT}, *BRCA*-wild-type; *BRCA*^{mut/+}, *BRCA*-mutated; CRS,

chemotherapy response score; NGS, next-generation sequencing; OS, overall survival; PFS, progression-free survival; CR, complete response; PR, partial response; PGD, progressive disease.